These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 32936732)

  • 41. SARS-CoV-2 vaccines: a triumph of science and collaboration.
    Golob JL; Lugogo N; Lauring AS; Lok AS
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33822773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coronavirus Disease 2019 Vaccine Development: An Overview.
    Sumirtanurdin R; Barliana MI
    Viral Immunol; 2021 Apr; 34(3):134-144. PubMed ID: 32985963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapidly Evolving SARS-CoV-2: A Brief Review Regarding the Variants and their Effects on Vaccine Efficacies.
    Nawaz S; Janiad S; Fatima A; Saleem M; Fatima U; Ali A
    Infect Disord Drug Targets; 2024; 24(4):58-66. PubMed ID: 38178666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COVID-19 vaccine breakthrough infections.
    Gupta RK; Topol EJ
    Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
    [TBL] [Abstract][Full Text] [Related]  

  • 45. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
    Jin Y; Hou C; Li Y; Zheng K; Wang C
    Front Immunol; 2021; 12():821538. PubMed ID: 35126377
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
    Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
    Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines.
    Zhu C; Pang S; Liu J; Duan Q
    Drugs; 2024 Apr; 84(4):403-423. PubMed ID: 38652356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19.
    Karthik K; Senthilkumar TMA; Udhayavel S; Raj GD
    Hum Vaccin Immunother; 2020 Dec; 16(12):3055-3060. PubMed ID: 32845733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-CoV-2 reinfection and implications for vaccine development.
    Nainu F; Abidin RS; Bahar MA; Frediansyah A; Emran TB; Rabaan AA; Dhama K; Harapan H
    Hum Vaccin Immunother; 2020 Dec; 16(12):3061-3073. PubMed ID: 33393854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.
    Salimi-Jeda A; Abbassi S; Mousavizadeh A; Esghaie M; Bokharaei-Salim F; Jeddi F; Shafaati M; Abdoli A
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108232. PubMed ID: 34673335
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pfizer COVID vaccine protects against worrying coronavirus variants.
    Callaway E
    Nature; 2021 May; 593(7859):325-326. PubMed ID: 33963317
    [No Abstract]   [Full Text] [Related]  

  • 54. Evolution of SARS-CoV-2: A prediction on the lineages and vaccine effectiveness.
    Priyanka ; Choudhary OP; Singh I
    Travel Med Infect Dis; 2021; 40():101983. PubMed ID: 33548551
    [No Abstract]   [Full Text] [Related]  

  • 55. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.
    Wang Y; Yang C; Song Y; Coleman JR; Stawowczyk M; Tafrova J; Tasker S; Boltz D; Baker R; Garcia L; Seale O; Kushnir A; Wimmer E; Mueller S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34193524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
    Pishesha N; Harmand TJ; Rothlauf PW; Praest P; Alexander RK; van den Doel R; Liebeskind MJ; Vakaki MA; McCaul N; Wijne C; Verhaar E; Pinney W; Heston H; Bloyet LM; Pontelli MC; Ilagan MXG; Jan Lebbink R; Buchser WJ; Wiertz EJHJ; Whelan SPJ; Ploegh HL
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34654739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The long road.
    Cohen J
    Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
    [No Abstract]   [Full Text] [Related]  

  • 59. Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms.
    Bayat M; Asemani Y; Najafi S
    Int Immunopharmacol; 2021 Aug; 97():107679. PubMed ID: 33930707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.
    Mallapaty S
    Nature; 2021 Jun; 594(7862):161-162. PubMed ID: 34089030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.